Foliglurax Enters Phase II Trial for Treatment of Parkinson's Patients

News   Jul 10, 2017 | Original Story from Prexton Therapeutics

 
Prexton Therapeutic's Parkinson's Drug Candidate, Foliglurax, Enters Phase II Trial
 
 
 

RELATED ARTICLES

Processed Meats Associated with Manic Episodes

News

Analysis of over 1,000 people with and without psychiatric disorders has shown that nitrates—chemicals used to cure meats such as beef jerky, salami, hot dogs and other processed meat snacks—may contribute to mania, an abnormal mood state.

READ MORE

Orexin Neurons are Promising Target for Medications to Treat Binge Eating

News

The researchers studied female rats fed a control diet or a sugary, high-fat diet that causes weight gain and binge eating patterns.

READ MORE

New Target Protein for Colon Cancer Identified

News

Researchers at Boston University School of Medicine (BUSM) have identified a new potential target protein (c-Cbl) they believe can help further the understanding of colon cancer and ultimately survival of patients with the disease.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Neuroscience

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy